Personalised medicine takes into consideration the interindividual differences amongst people, which may be responsible for the variability seen in response to a therapeutic intervention in any disease. When this epistemologic knowledge is applied to clinical oncology care, the exciting field is known as personalised cancer medicine -a field that has now evolved to 'precision medicine'. This knowledge enables the clinician to tailor the right dose of oncology therapeutic to the right subpopulation of cancer patients who will likely respond to the intervention, thereby resulting in greater therapeutic success and decreased 'financial toxicity' [1] to cancer patients, families and caregivers.
However, the road to success in personalised cancer care is beset with many difficulties in the practical realm, including the lack of reliable biomarkers, the inability to identify an accurate signature biomarker panel for each cancer type, the variability between patients diagnosed with the same cancer, etc. However, advances in modern diagnostic techniques and next-generation sequencing methodologies have provided some opportunities to mitigate the challenges in better informing the clinician regarding the best therapeutic strategies for a particular cancer type or patient. Nonetheless, significant limitations remain in clinical practice, and these adversely affect the best options available to the cancer patient who also has to bear the rising costs of cancer care.
Population pharmacogenomics
At the intermediate or late discovery stages of the drug development pipeline, population pharmacogenetics can help in optimising clinical trial design by stratifying populations, in optimising drug dosage for the appropriate patients, and in identifying patients at risk for adverse drug events [2] . The stratification of the clinical trial population into non-responders, responders, and hyper-responders can lead to a better designed trial that will include or exclude appropriate subpopulations for improved safety and better targeted efficacy. In this way, treatment can be personalised for the candidate subpopulation who will benefit the most from it without exposing them to the undue risks of serious adverse events. This will also translate into significant cost benefits and time savings. We recently reported [3] that the CYP2D6 genotype is not a robust predictor of the CYP2D6 ultrarapid metaboliser status in a comparative clinical pharmacogenomics study in the Cuban population. We also described the accurate frequency of CYP2D6 ultrarapid metabolisers in the Spanish population to be 5.34% when considering only the active alleles instead of counting just the multiplicated alleles [4] . We have reviewed elsewhere the applicability of pharmacogenetics to personalised medicine in the Latin American population, which exhibits large genetic variability [5] , as well as the evidence for personalising therapy in the pharmacogenetics of pain [6] and nociceptors. We have previously described [7] the architecture of signature microRNA (miRNA) regulatory networks comprising novel bifunctional cancer miRNAs that may play dual roles in the chemoprevention against, and chemoresistance to, various cancers. This mechanism may be partly explained by stress constraints in the cancer cell and/or by temporal or spatial differences in the tumour milieu. We have also described long non-coding RNA (lncRNA)-miRNA regulatory interactions in cancer translational medicine [8] . It follows that a pharmacodynamic/pharmacogenomic (PD/PG) model, which encapsulates both signature chemoresistance miRNAs and/ or lncRNAs and the corresponding signal transduction pathways, would be a useful value-addition in combating chemoresistance and augmenting the therapeutic success of cancer chemotherapy [9] . This model has been ably demonstrated by Wiliam Jusko's group [10] with the PD/ PG model of insulin resistance genes in skeletal muscle of adrenalectomised rats after dosing with methylprednisolone. Recently, Dalin et al. [11] used integrated genomic analyses to identify a high prevalence (70%) of oncogenic fusion genes in myoepithelial carcinoma, an aggressive salivary gland cancer, and implicated the TGFBR3-PLAG1 novel gene fusion in 15% patients as a hallmark of this lethal cancer. Savage et al. [12] screened patientderived xenografts (PDX) from triple-negative breast cancer (TNBC) patients and reported the heterogeneous expression of EGFR-high and EGFR-low cells in primary and metastatic tumours with only a subset of patients responsive to EGFR inhibition by gefitinib thus strengthening the case for potential patient stratification for the personalised therapeutic intervention. Das et al. [13] used NanoString technology to analyse gastric tumours from a Phase 3 Japanese clinical study and observed that Wnt5A downregulation is a predictor of improved progressionfree survival (PFS) in therapy with anticancer drug S-1 but not with irinotecan plus S-1 regimen, thus holding promise for improving chemotherapy efficacy. With prior knowledge of loss-of-function mutations in the PALB2 gene in breast cancer, Myszka et al. [14] used targeted massively parallel sequencing to confirm that Polish and Ukrainian women exhibit two frameshift deletions (509_510del and 172_175del) in PALB2, which should likely be included in genetic testing for predisposition to not just breast, but also ovarian, cancer in these populations.
Population pharmacometrics
Pharmacometrics is an umbrella term that includes quantitative measures of drug, disease, and clinical trial information with broad applicability in drug development, regulatory assessment and therapeutic decisions in the clinic [15] . With its unique time-saving and cost-reduction benefits, the pharmacometric approach in the form of model-based drug development (MBDD), is fast becoming the gold standard in discovery research in the biopharmaceutical industry as well as in the regulatory domain as it facilitates critical 'go/no-go' decisions in the drug discovery pipeline as well as allometric scaling in pharmacokinetics (PK) for safe 'first-in-man' doses of test compounds [9] . However, more work needs to be done to bring the benefits of the pharmacometric approach to the patient's bedside in the hospital.
Ciccolini et al. [16] developed a PK/PD model to identify an optimal metronomic chemotherapy protocol with gemcitabine and reported that the metronomic gemcitabine resulted in a 40%-50% decrease in tumour mass, which was not seen in the standard gemcitabine regimen. Majid et al. [17] performed population pharmacometric analyses by developing a population PK model of eribulin. They combined data from seven Phase 1 studies, one Phase 2, and one Phase 3 study, as well as a PK/PD model of efficacy/tumour response, to shed light on eribulin exposure-efficacy relationships to better inform clinicians in the management of metastatic breast cancer. In patients with gastrointestinal tumor (GIST) treated with intermittent sunitinib, Schindler et al. [18] constructed pharmacometric PK/PD models to demonstrate that early changes in the 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) may serve as a useful predictor of long-term outcome and overall survival. As the circulating tumor cells (CTC) could be a potential surrogate marker for prostate-specific antigen (PSA) in metastatic castration resistant prostate cancer, Wilbaux et al. [19] developed a semi-mechanistic pharmacometric model comprising Kinetic/PD (K/PD) compartments for chemotherapy and hormonotherapy, and a cell lifespan model to address the CTC kinetics, which would be useful in therapeutic adjustments during the course of treatment.
Interestingly, the heightened interest in the use of immunopharmaceuticals in oncology in recent times stems from their benefits in enhancing the overall response rate and PFS of the cancer patient with manageable adverse effects; however, the associated steep costs of these drugs can make it prohibitively expensive in developing countries with limited or no insurance coverage, and nonetheless expensive in developed countries where health management organisations decide how much will be covered and what co-payments will accrue. We have recently discussed the 'financial toxicity' and pharmacometrics of olaratumab [20] , an anti-PDGFR alpha monoclonal antibody (mAb), which recently received accelerated approval, orphan drug status, fast track and breakthrough designation from the FDA as well as conditional marketing authorisation by the EMA's accelerated assessment program [21] , for the treatment of inoperable soft tissue sarcomas, a heterogeneous group of cancers that comprise around 50 histiologic subtypes. Given this complex heterogeneity in the sarcomas, the pharmacometric approaches can help investigate whether the subpopulations of patients with higher PDGFR alpha expression correlate with enhanced PFS, or whether any subpopulation of patients that express PDGFR alpha may fail to respond to olaratumab monotherapy, but may respond to the combination of olaratumab with doxorubicin, the latter being the current standard of care [20] . We have also previously delineated the pharmacometrics and systems pharmacology of anti-PD-1 mAb nivolumab [22] , which has recently received accelerated approval from the FDA for advanced hepatocellular carcinoma [23] , metastatic melanoma [24] , metastatic renal cell carcinoma (RCC) [25] , and advanced squamous non-small cell lung cancer (NSCLC) [26] . Given that PD-L1, the ligand for PD-1, is a weak biomarker in clinical practice [22] , the pharmacometric model predictions for identifying the best responders to nivolumab therapy after patient stratification, coupled with immunopharmacogenomic assessments would enable personalising the therapy by tailoring the right drug to the right patients. Indeed, coupling the pharmacometric approaches with pharmacogenomic data in immuno-oncology, as with other oncotherapeutics, may likely provide a better platform to the clinician to render personalised care to the cancer patient.
Perspectives on the future 1 . The main stakeholders, such as pharmacometricians and medical oncology clinicians, should work together in concert to enable the benefits of modelling and simulation to be brought to the cancer patient's bedside in the clinic. Patient data that are already digitally available in the Electronic Medical Record (EMR) or Electronic Health Record (EHR) may be used effectively to initiate such a collaborative effort without any need for additional funding. 2. The development of canonical PK/PD/PG models that encompass the entire gamut of information on the drug, specific cancer, and clinical trials, including the key triad of PK, PD, and PG data, as well as data on tissue and circulating biomarkers, and potential companion diagnostics right from early discovery through Phase 0 or microdosing studies and into Phase 4 postmarketing surveillance, can help build a robust and reliable model based on both pharmacogenomics and pharmacokinetics. This model will likely translate into benefits for the clinician and the patient. 3. Despite advances in pharmacogenomics, there is an unmet need for validated cancer biomarkers or a reliable signature panel of biomarkers for each cancer type. Pharmacometric model-based approaches can be harnessed to query and identify these disease oncosignatures rapidly, which can then be validated in the laboratory and clinic. 4. The pharmacometric modelling and simulation strategies can help to lower the 'financial toxicity' to cancer patients, families and caregivers through hastening personalised cancer care to the right subpopulation of patients.
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